Inflection Points: The Next Revolution: From the Information to the Automation Age
The progression from one economic era to the next usually brings a healthy mix of excitement and opportunity along with uncertainty and ... By Scott Helfstein
Thoroughly researched perspectives and commentary on the trends shaping global markets. Subscribe to Updates →
Exploring a range of subjects as diverse as our product lineup.
The progression from one economic era to the next usually brings a healthy mix of excitement and opportunity along with uncertainty and ... By Scott Helfstein
‘The DISRUPT Framework’ is a quarterly exploration of artificial intelligence (AI), its profound impact on the world, and investment opportunities. Each edition will ... By Billy Leung
Artificial intelligence starts to make real money, computer chips get cheaper as competition rises, and ride share firms now want cars to ... By Global X Research Team
Lithium prices return to growth, tech giants prioritise AI investments, and the US grants billions to domestic semiconductor firms. Join us in ... By Global X Research Team
The return of operating leverage may be one of the most important but underappreciated developments in 2024 and could be quietly driving ... By Scott Helfstein
Drug development pipelines are the lifeblood of the pharmaceutical industry. It is crucial for investors to understand milestones like FDA approvals and ... By Global X Research Team
Big tech re-double their AI pursuits, drug makers capitalise on weight loss demand, and the end of the PC slump. Join us ... By Global X Research Team
Digital platforms drive record spending, new ‘miracle’ weight-loss drug approvals, and the US begins expansion of cybersecurity workforce. Join us in the ... By Global X Research Team
We believe the healthcare system is at a turning point, leveraging digital health technologies to render longstanding inefficiencies in healthcare a thing ... By Global X Research Team
Artificial intelligence improves drug discovery efficiency, US locks down their lithium supply for the future, and another tech titan enters the generative ... By Global X Research Team
The United States Food and Drug Administration (FDA) approved 45 new drugs in 2022.1 Though the number of approvals was the lowest ... By Global X Research Team
Patience can be a virtue in the biotech and genomic space, as next-generation biotech treatments do not hit the market overnight. However, ... By Global X Research Team
Editor’s Note: For terms in sea green, full glossary is included at the end with terms listed in the order that they appear. ... By Arelis Agosto
This document is issued by Global X Management (AUS) Limited (“Global X”) (Australian Financial Services Licence Number 466778, ACN 150 433 828) and Global X is solely responsible for its issue. This document may not be reproduced, distributed or published by any recipient for any purpose. Under no circumstances is this document to be used or considered as an offer to sell, or a solicitation of an offer to buy, any securities, investments or other financial instruments. Offers of interests in any retail product will only be made in, or accompanied by, a Product Disclosure Statement (PDS) which is available at www.globalxetfs.com.au. In respect of each retail product, Global X has prepared a target market determination (TMD) which describes the type of customers who the relevant retail product is likely to be appropriate for. The TMD also specifies distribution conditions and restrictions that will help ensure the relevant product is likely to reach customers in the target market. Each TMD is available at www.globalxetfs.com.au.
The information provided in this document is general in nature only and does not take into account your personal objectives, financial situations or needs. Before acting on any information in this document, you should consider the appropriateness of the information having regard to your objectives, financial situation or needs and consider seeking independent financial, legal, tax and other relevant advice having regard to your particular circumstances. Any investment decision should only be made after obtaining and considering the relevant PDS and TMD.
This document has been prepared by Global X from sources which Global X believes to be correct. However, none of Global X, the group of companies which Mirae Asset Global Investments Co., Ltd is the parent or their related entities, nor any of their respective directors, employees or agents make any representation or warranty as to, or assume any responsibility for the accuracy or completeness of, or any errors or omissions in, any information or statement of opinion contained in this document or in any accompanying, previous or subsequent material or presentation. To the maximum extent permitted by law, Global X and each of those persons disclaim all any responsibility or liability for any loss or damage which may be suffered by any person relying upon any information contained in, or any omissions from, this document.
Investments in any product issued by Global X are subject to investment risk, including possible delays in repayment and loss of income and principal invested. None of Global X, the group of companies of which Mirae Asset Global Investments Co., Ltd is the parent, or their related entities, nor any respective directors, employees or agents guarantees the performance of any products issued by Global X or the repayment of capital or any particular rate of return therefrom.
The value or return of an investment will fluctuate and an investor may lose some or all of their investment. All fees and costs are inclusive of GST and net of any applicable input tax credits and reduced input tax credits, and are shown without any other adjustment in relation to any tax deduction available to Global X. Past performance is not a reliable indicator of future performance.
The information provided in this document is general in nature only and does not take into account your personal objectives, financial situations or needs. Before acting on any information in this document, you should consider the appropriateness of the information having regard to your objectives, financial situation or needs and consider seeking independent financial, legal, tax and other relevant advice having regard to your particular circumstances. Any investment decision should only be made after obtaining and considering the relevant PDS and TMD.
This document has been prepared by Global X from sources which Global X believes to be correct. However, none of Global X, the group of companies which Mirae Asset Global Investments Co., Ltd is the parent or their related entities, nor any of their respective directors, employees or agents make any representation or warranty as to, or assume any responsibility for the accuracy or completeness of, or any errors or omissions in, any information or statement of opinion contained in this document or in any accompanying, previous or subsequent material or presentation. To the maximum extent permitted by law, Global X and each of those persons disclaim all any responsibility or liability for any loss or damage which may be suffered by any person relying upon any information contained in, or any omissions from, this document.
Investments in any product issued by Global X are subject to investment risk, including possible delays in repayment and loss of income and principal invested. None of Global X, the group of companies of which Mirae Asset Global Investments Co., Ltd is the parent, or their related entities, nor any respective directors, employees or agents guarantees the performance of any products issued by Global X or the repayment of capital or any particular rate of return therefrom.
The value or return of an investment will fluctuate and an investor may lose some or all of their investment. All fees and costs are inclusive of GST and net of any applicable input tax credits and reduced input tax credits, and are shown without any other adjustment in relation to any tax deduction available to Global X. Past performance is not a reliable indicator of future performance.